NEW YORK (GenomeWeb) – Interpace Diagnostics today announced securities purchase agreements that are anticipated to raise $4 million in gross proceeds.

The firm said it has entered into a securities purchase agreement with three undisclosed institutional investors to purchase an aggregate of 855,000 shares of common stock in a registered direct offering. In a private placement, it also has agreed to sell warrants to the same investors to purchase 855,000 shares of its common stock at $4.69 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.